A tetraethylene glycol coat gives gold nanoparticles long in vivo half-lives with minimal increase in size by Willett, Julian D. S. et al.
© 2017 Willett et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of Nanomedicine 2017:12 2581–2592
International Journal of Nanomedicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2581
O r I g I N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IJN.S121486
a tetraethylene glycol coat gives gold 
nanoparticles long in vivo half-lives with minimal 
increase in size
Julian Ds Willett
Marlon g lawrence
Jennifer c Wilder
Oliver smithies†
Department of Pathology and 
laboratory Medicine, University 
of North carolina at chapel hill, 
chapel hill, Nc, Usa
†Dr Oliver smithies passed away 
on January 10, 2017
Abstract: In this study, we describe the experiments determining whether coating gold 
nanoparticles with tetraethylene glycol (TEG) provides pharmacologically relevant advantages, 
such as increased serum half-life and resistance to protein adsorption. Monodisperse TEG-coated, 
NaBH
4
-reduced gold nanoparticles with a hydrodynamic size comparable to albumin were 
synthesized by reducing gold chloride with NaBH
4
 under alkaline conditions in the presence of 
TEG-SH. The particles were characterized by gel electrophoresis, column chromatography, and 
transmission electron microscopy. The nanoparticles were subsequently injected intravenously 
into mice, and their half-lives and final destinations were determined via photometric analysis, 
light microscopy (LM), and transmission electron microscopy. The TEG particles had a long 
half-life (~400 minutes) that was not influenced by splenectomy. After 500 minutes of injection, 
TEG particles were found in kidney proximal tubule cell vesicles and in spleen red and white 
pulp. The particles induced apoptosis in the spleen red pulp but not in white pulp or the kidney. 
Some of the TEG particles appeared to have undergone ligand exchange reactions that increased 
their charge. The TEG particles were shown to be resistant to nonspecific protein adsorption, 
as judged by gel electrophoresis and column chromatography. These results demonstrate that 
naturally monodisperse, small-sized gold nanoparticles coated with TEG have long in vivo 
plasma half-lives, are minimally toxic, and are resistant to protein adsorption. This suggests that 
a TEG coating should be considered as an alternative to a polyethylene glycol coating, which 
is polydisperse and of much larger size.
Keywords: tetraethylene glycol, tetraethylene glycol coating, polyethylene glycol, splenectomy, 
spleen clearance, kidney clearance
Introduction
Preexisting data show that nanoparticle coating impacts their removal from circulation.1 
PEG coating has been found to be particularly useful, with coated particles remaining 
in serum for hours, minimally interacting with proteins that could trigger removal from 
circulation, and causing minor physiological consequences in the organs that filter 
them, notably the spleen and kidney.2–4 However, PEG is a large compound (typical 
formulations used have a molecular weight .2 kDa) that can increase hydrodynamic 
radius (HDR), limiting particle diffusion into target cells.4 PEG is also polydisperse, 
necessitating purification and limiting control of variables when the particles are used 
in medical applications. Extensive work has been done studying the in vivo behavior 
of these PEG nanoparticles,1–5 although a number of coats have yet to be investigated 
in mouse models that could overcome limitations presented by PEG. Among these, 
tetraethylene glycol (TEG) is particularly attractive because it has been found to confer 
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properties comparable to those of PEG in vitro, but with 
less impact on overall particle size.5–9 Currently, no articles 
document the effect of this coat on nanoparticles in vivo. 
We here describe the results of experiments aimed at rectify-
ing this absence using particles synthesized with a gold core 
to facilitate observation with both light microscopy (LM) 
and transmission electron microscopy (TEM). We character-
ized the TEG-coated nanoparticles, determined their plasma 
half-life, and studied their uptake and cytotoxic effects on 
the kidney and spleen. Our results show that TEG coating 
confers benefits similar to a PEG coating, but with a smaller 
increase in HDR.
Materials and methods
chemicals
Gold(III) chloride trihydrate, reduced glutathione (GSH), and 
TEG-SH were obtained from Sigma Aldrich (Natick, MA, 
USA) (product codes: G4022, G4251, and 767751, respec-
tively). Phosphate-buffered saline (PBS) without calcium and 
magnesium was obtained from Corning Cellare (Corning, 
NY, USA) (product code: 01-031-CV).
Teg-coated, NaBh4-reduced gold 
nanoparticle synthesis
Synthesis of TEG-coated particles was based on a modifica-
tion of Smithies et al’s10 synthesis of GSH-coated nanopar-
ticles. Synthesis was conducted in the following manner at 
room temperature while stirring vigorously with a Teflon-
magnetic bar. To a 125 mL Wheaton glass bottle were added 
1) 18 mL of water, 2) 800 µL of 0.1 M borax, Na
2
B
4
O
7
, 
3) 40 µL of 5 M TEG-SH (10 mM final concentration), and 
4) 800 µL of 25 mM HAuCl
4
. After 1 minute, 5) 160 µL 
of freshly prepared 0.5 M NaBH
4
 was added. This mixture 
was left overnight without stirring and then concentrated 
to ~200 µL with a 4 mL Amicon 30 kDa filter and stored at 
4°C after diluting as described subsequently.
gold nanoparticle dilution
To dilute nanoparticles to a standardized concentration, 
absorbance at 260 nm of 1/1,000 nanoparticle dilution was 
determined. The particle preparation was then diluted with 
water to a concentration that yielded an absorbance of 0.25 
when diluted 1/1,000. The final volume was typically 300 µL.
gel electrophoretic assessment of gold 
nanoparticle size distribution
To determine nanoparticle consistency between batches 
and size dispersity, 1 µL of nanoparticle formulations was 
mixed with 10 µL of a glycerol-containing loading buffer, 
LG (200 µL 80% v/v glycerol plus 80 µL 0.5 M NaHCO
3
, 
bromophenol blue to 0.05%) plus 1.2 µL of 10× PBS. The 
mixture was loaded into a Biorad 4%–20% Mini-PROTEAN 
TGX precast protein gel (BioRad Laboratories, Hercules, 
CA, USA) using 1× Tris/glycine running buffer without 
sodium-dodecyl sulfate (SDS). The gel was electrophoresed 
at 200 V until the bromophenol blue band neared the bottom 
of the gel. Gels were scanned with an Epson Perfection 3170 
Photo, J161A scanner (Epson, Long Beach, CA, USA) set to: 
document type: reflective, 24-bit color, resolution: 720 dpi, 
and Unsharp Mask checked.
gold nanoparticle core diameter 
determination
TEM was used to assess gold nanoparticle core diameter. 
Particles were diluted 1:250 with water, and 1 µL was placed 
on a copper glow-discharged electron microscope grid and 
left to dry. The core diameters of at least 1,000 nanoparticles 
were measured, and an average particle core diameter was 
calculated using the ImageJ program (software available 
from the National Institutes of Health).
gold nanoparticle hDr determination
Size-exclusion chromatography was performed using a 
Superdex 200 10/300 GL column with PBS as the eluting 
buffer. Standards included IgG, bovine serum albumin, and 
ovalbumin. Absorbance was measured at 260 nm.
Injection of gold nanoparticles and blood 
collection from mice
Female B6 mice (B6 Jax), some splenectomized and permit-
ted to heal for at least a week, were obtained, weighed, and 
fed normal diets. 1) A blood sample was collected from the 
retro-orbital sinus in one eye under light isoflurane anesthesia 
using a heparinized 70 µL microcapillary tube. 2) A mixture 
of 90 µL of gold nanoparticles (1/1,000 OD
260
 
nm
 =0.25) and 
10 µL 10× PBS was subsequently injected into the retro-
orbital sinus of the other eye.11 3) Approximately 45 µL of 
blood was collected at 5, 166, 333, and 500 minutes. 4) At the 
end of each experiment, animals were exposed to isoflurane 
until they became unconscious and were then sacrificed by 
cervical dislocation. 5) Kidneys and spleens were collected, 
fixed, and stored in Karnovsky’s fixative for subsequent 
analysis. 6) All experiments were repeated with different 
batches of particles using at least three animals for each test. 
All mouse experimental procedures were performed follow-
ing protocols approved by the Institutional Animal Care and 
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Use Committee (IACUC) at the University of North Carolina 
(Smithies 14-004).
half-life determination of Teg-coated 
gold nanoparticles
The microcapillary tubes containing blood samples were 
centrifuged for 2 minutes with an MB International Micro-
Capillary Centrifuge (Damon, Needham, MA, USA), and 
the plasma region was scanned on an Epson J161A Scanner 
set to: document type: film, document type setting: positive 
film, 24-bit color, resolution: 1,000 dpi, and Unsharp Mask 
checked. ImageJ was used to calculate the plasma gray value 
at the center of each tube, and from this value, a relative 
nanoparticle concentration was calculated relative to gray 
values of serial dilutions of standard concentration nanopar-
ticle preparations (1:15, 1:20, 1:25, 1:30, 1:40, 1:60, 1:100, 
and 1:250 dilutions). This relative concentration was then 
adjusted for tube-related effects by subtracting the preinjec-
tion sample relative concentration (typically close to zero). 
Following this measurement, the alpha-phase (distribution 
phase) length was determined by plotting time against relative 
concentration for plasma samples of a batch of particles and 
locating the point on the curve where the decline in relative 
concentration became roughly linear, delineating the end of 
the alpha phase (Figure 1).12 Only times after the estimated 
alpha phase were used during calculation of half-life as 
this is when half-life can be most accurately assessed.12 
The natural logarithms of beta-phase relative concentra-
tions were then plotted against time. Plasma half-lives were 
determined assuming first-order clearance. The slope of 
the subsequent beta phase, Slopeβ, was determined using 
Microsoft Office plots of collected data.12 This value was 
used to determine half-life using the following pharmacoki-
netic equations with each individual animal experiment. The 
base formula for first-order elimination is C = C
0
⋅e-Slopeβ⋅t.12 
Half-life (t
1/2
) was defined as the time when C C= 1
2 0
. Thus, 
half-life: t
1 2
2 0 693= =ln 
Slope Slope
( ) .
β β
 with the slope equating to: 
δ  
δ  
ln relative concentration
time
( )
.12
gel electrophoresis analysis of plasma 
samples
To observe potential changes in nanoparticle mobility dur-
ing circulation, 6 µL of plasma isolated from collected blood 
samples was mixed with 4.8 µL LG buffer and 1.2 µL 10× PBS. 
This mixture was electrophoresed at 200 V in a Tris/glycine 
4%–20% gradient gel without SDS. Voltage was applied 
until the bromophenol blue marker was close to the bottom of 
the gel casing. The gel was scanned using an Epson Scanner.
Tissue analysis
Tissue sectioning
Fixed kidney and spleen samples, taken from abnormally 
dark tissue when apparent, were embedded in LR white resin. 
At least two unstained and two toluidine blue-stained sections 
were examined by LM, and at least two ultrathin sections 
were examined by TEM for each batch of nanoparticles.
light microscopic analysis
Slides were analyzed using bright-field LM with and without 
bromophenol blue staining. Images were captured using 
Volocity imaging software from Perkin Elmer (Walthman, 
MA, USA). Images had their brightness adjusted using 
ImageJ to facilitate analysis.
Transmission electron microscopic analysis
Electron microscope images were obtained with a LEO 910 
Electron Microscope. Images were analyzed with Gatan 
Digital Micrograph provided by Gatan, Inc. (Pleasanton, 
CA, USA).
analysis of sections stained with terminal 
deoxynucliotidyl transferase dUTP nick end labeling 
(TUNel) TUNel reagent
Two sets of tissue for each experimental condition were 
stained with a Promega DeadEnd Colorimetric TUNEL Sys-
tem (Promega Corporation, Madison, WI, USA). For kidneys, 
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Figure 1 Time-dependent elimination of Teg-coated nanoparticles.
Notes: The dotted black line represents the logarithmic best-fit line used to 
determine alpha and beta phases.12 The blue line represents the linear best-fit line of 
all nanoparticle relative concentrations during the beta phase, which were used to 
determine half-life as described.12
Abbreviations: t1/2, half-life; Teg, tetraethylene glycol.
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three 200× images from one tissue slice and three 200× 
images from another slice were randomly selected from 
the cortical region (the observed region of particle uptake). 
Spleen images were collected similarly with emphasis on the 
regions containing both red and white pulps. Results were 
quantified by the ImageJ threshold analysis of the blue image 
produced after RGB split. The blue filter was chosen as it 
minimized background noise produced from staining and 
emphasized the bronze-colored TUNEL stain.
gold nanoparticle–salt interaction assay
To study interactions between TEG nanoparticles and com-
mon cations, a TEG nanoparticle preparation was mixed 
1:1 with 0.2 M KCl or 0.2 M CaCl
2
 and left for 5 minutes. 
Then, 4 µL of the mixture, 8 µL of LG buffer, and 1.3 µL 
of 10× PBS were electrophoresed in a 4%–20% Tris/glycine 
gel and scanned using an Epson Scanner.
gold nanoparticle–ph interaction assay
To measure the effect of pH on nanoparticle stability, as 
visualized by electrophoretic mobility differences, a TEG 
nanoparticle preparation was mixed 1:1 with dilute HCl or 
NaOH to give final pHs from 1 to 14. After leaving samples 
overnight, 8 µL of LG buffer and 1.3 µL of 10× PBS were 
added to 4 µL of sample, and aliquots were electrophoresed 
in a 4%–20% Tris/glycine gel. The gel was scanned using 
the Epson Scanner.
gold nanoparticle-glutathione ligand 
exchange assay
To determine whether intracellular concentrations of glu-
tathione are sufficient to induce ligand exchange reactions 
with TEG nanoparticles,13 a TEG nanoparticle preparation 
was mixed 1:1 with glutathione dissolved in water to yield 
aliquots with a final glutathione concentration of 0.1 mM (low 
concentration), 1 mM (low cellular concentration), 5 mM 
(medium cellular concentration), and 10 mM (high cellular 
concentration).14 Samples were left on a bench for 1 hour. 
Then, 8 µL LG buffer and 1.3 µL 10× PBS were added to 4 µL 
of sample. The mixture was electrophoresed in a 4%–20% 
Tris/glycine gel and scanned using an Epson Scanner.
statistical analyses
Half-lives and core diameters between batches of nanopar-
ticles and the number of TUNEL-positive cells between 
experimental and control samples were compared with JMP 9 
from the SAS Institute (Middleton, MA, USA) using one-way 
analysis of variance (ANOVA) with an alpha value of 0.01. 
Unless otherwise specified, numerical data are presented as 
mean ± standard error.
Results and discussion
The goal of these experiments was to determine whether a 
TEG-SH coat is useful for nanomedicine. TEG was chosen 
as a coat due to its small size and because of its chemical 
similarity to the widely used PEG. The primary findings were 
that 1) a TEG coating confers a long nanoparticle half-life, 
2) the kidney and spleen completely take up the TEG-coated 
particles, 3) TEG particles induce apoptosis in spleen red pulp 
cells although not in other splenic regions or the kidney, and 
4) TEG particles are initially unchanged in vivo; however, 
they are significantly modified by ligand exchange reactions 
by roughly a quarter of their half-life after injection.
Particles are consistently monodisperse
Gel electrophoresis of the TEG particles showed that they 
are monodisperse and have a negative charge despite TEG 
having no groups expected to ionize at this pH (Figure 2A).6 
This has been noted in a previous study.15
Teg particles have a consistent core 
diameter
Transmission electron microscopic analysis showed that 
batches of TEG nanoparticles have consistent core diameters 
between batches as the values were within a standard devia-
tion of each. The pooled core diameter of TEG nanoparticles 
was 4.76±0.74 nm (n=2,093) (Figure 2B and C). The TEG 
particles had a sharp, well-refined edge (Figure 2B and C). 
TEG particles were found to be unaffected by variations in 
the times of adding reagents.
Teg particles have consistent hDr
Hydrodynamic radii were compared by size-exclusion 
chromatography using a Superdex 200 column with PBS as 
the eluent buffer. On this column, fully excluded Dextran 
2000 eluted in fraction 20 and fully penetrant acetone 
eluted in fraction 49. Two batches of TEG particles eluted 
at fractions 33.4 (Figure 2D) and 34.2 (data not shown), 
indicating a size slightly smaller than bovine serum albumin, 
MW 66.5 kDa.16 Elution profiles showed that the particles 
are monodisperse (Figure 2D).
Teg particles absorb visible light
TEG particles are ruby colored due to an absorption maximum 
at 518 nm (Figure 2E). The color of the TEG particles is 
useful because it permits the determination of a sample’s 
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nanoparticle concentration and electrophoretic trends 
by equipment using visible light, which are readily available.
Teg particles have a long half-life
To determine whether a TEG coat increases nanoparticle half-
life, relative concentrations of serum-based nanoparticles 
were plotted semilogarithmically against time as previously 
described with data points in the beta elimination phase used 
for half-life determination (Figure 3).12 The pooled half-life 
of two batches of TEG particles was 421±32 min (n=8) 
with no significant variation in this measurement between 
the batches (P=0.31) (Figure 3). Thus, TEG particles have 
long and reproducible half-lives, supporting their potential 
as a coating agent. These samples yielded an average alpha-
phase length of 150±10 minutes.12 This half-life (~7 hours) 
of TEG-coated particles is largely determined by their HDR, 
which is slightly less than that of albumin.17 Particles of that 
size have been shown by Lawrence et al18 to traverse the 
renal glomerulus and be captured by proximal tubule (PT) 
cells. Larger sized PEG-coated particles do not traverse 
the glomerulus and so have longer half-lives and varied 
clearance profile (~20 hours).3 Gel electrophoresis suggests 
that despite the long half-life, the particles are modified 
during circulation with no unmodified material remaining 
by ~166 minutes (Figure 3).
splenectomy does not impact Teg 
particle half-life
To determine the role of the spleen in TEG particle clearance, 
animals were splenectomized and injected with particles. The 
particle half-lives were calculated as described. The pooled 
half-life for TEG particles in these splenectomized animals 
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Figure 2 characterization of Teg-coated gold nanoparticles.
Notes: (A) gel of Teg gold nanoparticle preparations. (B) TeM of Teg nanoparticles. (C) histogram of pooled Teg nanoparticle core diameters. (D) column chromatograph 
of Teg nanoparticles. (E) light spectrum of Teg nanoparticles.
Abbreviations: Teg, tetraethylene glycol; TeM, transmission electron microscopy.
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was 457±36 min (n=6; P=0.47 for splenectomized versus 
nonsplenectomized animals) (Figure 3A). The particles were 
modified during circulation similarly to mice that were not 
splenectomized (Figure S1). We conclude that the spleen is 
not the primary organ for clearing TEG nanoparticles from 
circulation (Figure 4D and E).
Tissue analysis
Teg particles are taken up by renal proximal 
tubule cells
Kidney tissue sections taken from animals 500 minutes 
after nanoparticle injection showed that the TEG nanopar-
ticles were accumulated in intracellular vesicles of PT cells 
(Figures 4 and 5). This shows that our TEG particles have 
passed through the glomerulus and have entered cells, most 
likely via endocytosis and diffusion.17 Clearance of our TEG 
particles from the renal ultrafiltrate was complete since the 
urine was devoid of particles. The particles do not appear to 
cause harm to renal PT cells as apoptosis studies yielded no 
significant difference in the number of apoptotic cells in the 
kidneys of these experimental animals compared to control 
animals (data not shown); however, it is possible that cellular 
pathways are altered as the particles proved toxic to cells in 
the spleen red pulp (Figure 6). These results were not changed 
when the mice were splenectomized (Figure S2).
Teg particles are collected in the spleen
Light microscopic analysis of splenic tissue shows particle 
accumulation throughout the organ in red and white pulps 
as visualized by the dark punctate not present on sections 
taken from mice injected with PBS (Figure 4D and E).19 
The extent of observed uptake is similar to the 5 nm PEG-
coated nanoparticles described by Zhang et al with a similar 
extent of uptake in the kidney and spleen.4 The punctu-
ate could not be definitively located on TEM sections as 
electron dense metals in the spleen, such as iron, looked 
similar to the particles, preventing effective assessment. 
The particles observed with LM in red pulp were likely 
taken up by macrophages in the region’s reticular meshwork 
(Figure 4D and E);19 previous work has found that injections 
of thorium dioxide and hemosiderin, an iron storage complex, 
are taken up by macrophages in this region, suggesting 
metallophilic characteristics.20 Particles collected in the 
white pulp were likely taken up by well-described metal-
lophilic macrophages present there (Figure 4D and E).19 
The particles were perhaps collected by the spleen due to 
exposure to serum compounds that could trigger aggregation 
and phagocytosis following ligand exchange, which is known 
to preferentially lead to splenic clearance with PEG-coated 
nanoparticles.3,5,13,21 A minority of particles would aggregate 
as splenectomized animal half-life results and column work 
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Figure 3 In vivo behavior of Teg-coated gold nanoparticles.
Notes: (A) One-way aNOVa of pooled nanoparticle half-lives. “splenect” refers to splenectomized animals. (B) Pharmacokinetic curve of Teg-coated particles with jittered 
natural logarithm concentrations. (C) gel of animal plasma following injection of Teg particles.
Abbreviations: aNOVa, analysis of variance; Teg, tetraethylene glycol.
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Figure 4 Thick section of mouse injected with Teg particles (A) Kidney stained with toluidine blue, 100×; (B) Kidney stained with toluidine blue, 400×; (C) Kidney, 400×; 
(D) spleen stained with toluidine blue, 100×; (E) spleen, 100×.
Abbreviations: Teg, tetraethylene glycol; PT, proximal tubule; rP, red pulp; WP, white pulp.
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Figure 5 (A–C) TeM of nonsplenectomized mouse kidney 500 minutes following injection with Teg nanoparticles.
Abbreviations: TeM, transmission electron microscopy; Teg, tetraethylene glycol.
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demonstrated an unchanged HDR 12.5 and 166 minutes after 
injection (Figure 7A).
Teg particles induce apoptosis in the spleen
There was no apparent nanoparticle-induced apoptosis in the 
kidney regardless of splenectomy status as TUNEL assay 
results yielded a comparable number of TUNEL positive 
cells between experimental and control samples (P.0.35). 
Spleen tissue had significantly increased TUNEL positive 
cells (predominantly localized to the red pulp) relative to 
control tissue with an average of 88±15 positive cells for 
experimental samples versus an average of 19±3 positive 
cells for control samples (P,0.001) (Figure 6). While TEG 
gold nanoparticles are collected promiscuously through the 
spleen, likely by macrophages per Larson et al’s13 work 
characterizing ligand-exchanged PEG-coated particles 
(Figure 4D and E), these results suggest that the nanoparticles 
taken up in the spleen red pulp, by perhaps reticular meshwork 
macrophages as previously described, are toxic.19 Thus, both 
TEG- and PEG-coated nanoparticles are toxic, albeit to dif-
ferent organs.3 However, the marginal zone and white pulp 
showed little apoptotic activity (Figure 6). These results 
reinforce the necessity to characterize nanoparticle-induced 
cellular pathways both for toxicology purposes and the use 
of particles’ apoptotic ability for use in treatment for hyper-
proliferative conditions.
Teg particles gain charge during circulation
There was a time-based increase in charge for TEG particles 
suggesting their modification (Figure 3C). The unmodified 
particle band was readily observed in the 12.5-minute lane but 
was no longer visible in the 166-minute sample (Figure 3C). 
Column data indicated no significant interaction of TEG 
particles with macromolecules based on minimal HDR 
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Figure 6 spleen sections exposed to TUNel assay reagents and processed using ImageJ for analysis.
Notes: (A) control unadjusted and (B) adjusted images. (C) experimental unadjusted, and (D) adjusted images.
Abbreviations: rP, red pulp; WP, white pulp.
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change 12.5 minutes (Figure 7A) and 166 minutes (data 
not shown) following injection compared to HDR before 
injection and upon mixing with plasma. This demonstrates 
that a majority of the particles are not reacting with other 
macromolecules and are resistant to protein adsorption, which 
is in agreement with other investigators’ ex vivo work.7–10 
The change in charge is thus likely due to interaction with 
small molecules, such as glutathione, that more readily 
 penetrate the particles’ TEG shield and trigger ligand exchange 
reactions.13 PEG-coated particles have been shown to undergo 
ligand exchange reactions, which also increase protein adsorp-
tion and their uptake by macrophages.13 The change is unlikely 
due to cations as gel electrophoresis illustrated that neither 
concentrated salts (0.1 M potassium, sodium, and calcium) 
(data not shown) nor physiological hydrogen or hydroxide 
ion concentrations elicited the observed change (Figure S3).22 
The change is also unlikely to be due to particle degradation 
as TEM revealed that nanoparticles collected from the plasma 
166 minutes after injection had comparable core diameters 
to TEG batches before injection with a pooled core diameter 
of 4.71±1.03 nm (n=228) (data not shown) contrasting with 
newly synthesized particles yielding a pooled core diameter of 
4.76±0.74 nm (n=2,093) (Figure 2B and C). The serum con-
centration of common thiols (GSH at 68.1 µM and cysteine 
at 79.6 µM) was found to be insufficient to elicit this reac-
tion (Figure 7B).9,13,23 However, intracellular concentrations 
of GSH (concentrations .1 mM) were found to increase 
nanoparticle charge similarly to what was observed in plasma 
samples, suggesting that the reaction may occur within cells 
(Figures 3C and 7B).14
Teg particles do not change size during circulation
Column chromatographic analysis of TEG particles mixed 
with wild-type mouse plasma and in plasma 12.5 minutes 
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Figure 7 TEG-coated gold nanoparticle modification assays.
Notes: (A) column data of Teg particles mixed ex vivo with wild-type mouse plasma and Teg particles in plasma (in vivo) 12.5 min following injection. (B) gel of Teg 
particles mixed with gsh for 1 hour (low concentration [0.1 mM], low cellular concentration [1 mM], medium cellular concentration [5 mM], and high cellular concentration 
[10 mM]).14
Abbreviations: gsh, glutathione; Teg, tetraethylene glycol.
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following nanoparticle injection demonstrated no significant 
nanoparticle–macromolecule interactions (Figure 7A). While 
aggregates were observed in the spleen, they likely do not 
influence the HDR due to a minority of particles aggregating. 
These results suggest that TEG confers “stealth” and stability 
to nanoparticles in the bloodstream, similar to PEG.1
Conclusion
Our results show that gold nanoparticles coated with TEG have 
a long half-life in circulation and are resistant to nonspecific 
protein adsorption. Thus, they are similar to PEG-coated 
nanoparticles.3 The protocol used to make these particles is 
reproducible as judged by consistent electrophoretic mobility 
and core diameters. The TEG-coated particles, which have 
a hydrodynamic size slightly less than albumin, traverse the 
glomerulus and are captured by proximal tubule cells to never 
reach the urine. The particle half-life was not altered by sple-
nectomy indicating that the spleen is not the primary clearing 
organ. The liver did not capture significant amounts of nanopar-
ticles. TEG particles in the circulation gained charge over time, 
suggesting that they undergo ligand exchange with intracellular 
thiols, such as glutathione. We conclude that TEG is a useful 
coating agent for gold nanoparticles since their synthesis yields 
monodisperse particles with a long half-life and resistance to 
protein adsorption. However, the toxicity of their gold cores 
must be further investigated because they remain in the kidney 
and induce apoptosis in spleen red pulp. As they can trigger 
apoptosis, it is possible that the particles interfere with other cell 
pathways, such as reuptake of glucose, even though they do not 
induce apoptosis in other tissue or cause the injected animals 
to show signs of distress. Such work could enable production 
of a safer nanoparticle and a novel chemotherapeutic if the 
particles’ toxicology was used against tumors.
Acknowledgments
This work was made possible by the University of North 
Carolina at Chapel Hill Summer Undergraduate Research 
Fellowship, Honors Carolina of the University of North 
Carolina at Chapel Hill, grants from the National Institutes 
of Health (HL49277 and DK080302), Robert Bagnell, Vicky 
Madden, and Kristen White for their assistance with electron 
and light microscopy, Dr Nobuyo Maeda for access to mice, 
J Ashley Ezzell and Kara Clissold for their assistance with 
TUNEL assays, Dr Daniel Kenan for his assistance in histo-
logical section cellular identification, and the late Dr Oliver 
Smithies for his invaluable guidance over the years.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Gref R, Domp A, Quellec P, et al. The controlled intravenous deliv-
ery of drugs using PEG coated sterically stabilized nanospheres. 
Adv Drug Del Rev. 1995;16(95):215.
 2. Dreaden EC, Austin L, Mackey M, El-Sayed M. Size matters: gold nanopar-
ticles in targeted cancer drug delivery. Ther Deliv. 2012;3(4):457–478.
 3. Cho WS, Cho M, Jeong J, et al. Acute toxicity and pharmacokinetics of 
13 nm-sized PEG-coated gold nanoparticles. Toxicol Appl Pharmacol. 
2009;236(1):16–24.
 4. Zhang XD, Wu D, Shen X, et al. Size-dependent in vivo toxicity of PEG-
coated gold nanoparticles. Int J Nanomedicine. 2011;6:2071–2081.
 5. Jong WHD, Borm PJ. Drug delivery and nanoparticles: applications 
and hazards. Int J Nanomedicine. 2008;3(2):133–149.
 6. Foos EE, Snow AW, Twigg ME, Ancona MG. Thiol-terminated Di-, 
Tri-, and tetraethylene oxide functionalized gold nanoparticles: a water-
soluble, charge-neutral cluster. Chem Mater. 2002;14(5):2401–2408.
 7. Kanaras AG, Kamounah FS, Schaumburg K, Kiely CJ, Brust M. Thioalky-
lated tetraethylene glycol: a new ligand for water soluble monolayer pro-
tected gold clusters. Chem Commun (Camb). 2002;20(26):2294–2295.
 8. Zheng M, Davidson F, Huang X. Ethylene glycol monolayer protected 
nanoparticles for eliminating nonspecific binding with biological 
molecules. J Am Chem Soc. 2003;125(26):7790–7791.
 9. Zheng M, Li Z, Huang X. Ethylene glycol monolayer protected nano-
particles: synthesis, characterization, and interactions with biological 
molecules. Langmuir. 2004;20(10):4226–4235.
 10. Smithies O, Lawrence M, Testen A, et al. Stable oligomeric clusters 
of gold nanoparticles: preparation, size distribution, derivatization, 
physical and biological properties. Langmuir. 2014;30:13394–13404.
 11. Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S. 
Retro-orbital injections in mice. Lab Anim (NY). 2011;40(5):155–160.
 12. Tomlin M. Pharmacology & Pharmacokinetics: A Basic Reader. London: 
Springer-Verlag London; 2010.
 13. Larson TA, Joshi PP, Sokolov K. Preventing protein adsorption and 
macrophage uptake of gold nanoparticles via a hydrophobic shield. 
ACS Nano. 2012;6(10):9182–9190.
 14. Hwang C, Sinskey AJ, Lodish HF. Oxidized redox state of glutathione 
in the endoplasmic reticulum. Science. 1992;257(5076):1496–1502.
 15. Schollbach M, Zhang F, Roosen-runge F, Skoda MWA, Jacobs RMJ, 
Schreiber F. Gold nanoparticles decorated with oligo (ethylene glycol) 
thiols: surface charges and interactions with proteins in solution. 
J Colloid Interface Sci. 2014;426:31–38.
 16. Masuelli MA. Study of bovine serum albumin solubility in aque-
ous solutions by intrinsic viscosity measurements. Adv Phys Chem. 
2013;2013:8.
 17. Smithies O. Why the kidney glomerulus does not clog: a gel permeation/
diffusion hypothesis of renal function. Proc Natl Acad Sci U S A. 2003; 
100(7):4108–4113.
 18. Lawrence MG, Altenburg MK, Sanford R, et al. Permeation of macro-
molecules into the renal glomerular basement membrane and capture 
by the tubules. PNAS. 2017;114(11):2958–2963.
 19. Cesta MF. Normal structure, function, and histology of the spleen. 
Toxicol Pathol. 2006;34(5):455–465.
 20. Blue J, Weiss L. Electron microscopy of the red pulp of the dog spleen 
including vascular arrangements, peri-arterial macrophage sheaths, ellip-
soids, and the contractive reticular meshwork. Am J Anat. 1981;161(2): 
189–218.
 21. Aggarwal P, Hall JB, Mcleland CB, Dobrovolskaia MA, Mcneil SE. 
Nanoparticle interaction with plasma proteins as it relates to particle 
biodistribution, biocompatibility and therapeutic efficacy. Adv Drug 
Deliv Rev. 2009;61(6):428–437.
 22. Pfeiffer C, Rehbock C, Hühn D, et al. Interaction of colloidal nano-
particles with their local environment: the (ionic) nanoenvironment 
around nanoparticles is different from bulk and determines the physico-
chemical properties of the nanoparticles. J R Soc Interface. 2014; 
11(96):20130931.
 23. Granholm DE, Neil Reese R, Granholm NH. Agouti alleles alter cysteine 
and glutathione concentrations in hair follicles and serum of mice (Ay/a, 
AwJ/AwJ, and a/a). J Invest Dermatol. 1996;106(3):559–563.
International Journal of Nanomedicine 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2591
Tetraethylene glycol coat gives gold nanoparticles long in vivo half-life
Supplementary materials
Figure S1 gel of splenectomized animal plasma 25, 166, 333, and 500 minutes following injection of Teg particles.
Abbreviation: Teg, tetraethylene glycol.
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Figure S2 Thick kidney section of splenectomized mouse injected with (A) Teg particles, section stained with toluidine blue, 100×; (B) Teg particles, section stained with 
toluidine blue, 400×; (C) Teg particles, 400×.
Abbreviations: Teg, tetraethylene glycol; PT, proximal tubule.
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Figure S3 Gel of TEG particles mixed with acid/base to a final pH of 1 to 14.
Abbreviation: Teg, tetraethylene glycol.
